Head to Head Economic Evaluation of Two Genomic Profiles of Recurrence Risk for Breast Cancer, Mammaprint Versus Oncotype DX, in Spain

Abstract

OMS and drugs, inpatient rehabilitation, patients' co-payments. Indirect costs (IC: sick leave, premature retirement, premature mortality) were estimated by 2010 gross domestic product/capita/day. Costs and quality-adjusted life-years (QALYs) were discounted by 3% per annum. Strategies with significantly different QALYs/ patient-year (PY) were compared by CUA, remaining strategies by cost-minimization analysis. Results: